A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Slides:

Advertisements

Similar presentations

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

Advertisements

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Wijtske Annema, PhD, Hendrik M

Robert Roberts, MD, FRCPC, MACC Canadian Journal of Cardiology

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

James H. O’Keefe, MD, Salman K. Bhatti, MD, Ata Bajwa, MD, James J

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

The prevalence of abdominal aortic aneurysm is consistently high among patients with coronary artery disease Jussi A. Hernesniemi, MD, PhD, Ville Vänni,

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update

Chapter 2: Pharmacological cholesterol-lowering treatment in adults

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD, Matthew K. Ito,

M.E. Jørgensen, C. Andersson, S. Venkatesan, R.D. Sanders

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Normal Weight-Central Obesity Is Associated with the Highest Mortality Risk in Older Adults with Coronary Artery Disease*† Saurabh Sharma, MD, John A.

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

Common Single-Nucleotide Polymorphisms Act in Concert to Affect Plasma Levels of High-Density Lipoprotein Cholesterol Victor Spirin, Steffen Schmidt,

Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study Tim Christen, MSc, Stella.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Muhammad Amer, MD, MHS, FACP, Rehan Qayyum, MD, MHS

Primary and Secondary Prevention of Cardiovascular Disease

APOC3, Coronary Disease, and Complexities of Mendelian Randomization

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease Anna Maria Izquierdo-Porrera,

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

The prevalence of abdominal aortic aneurysm is consistently high among patients with coronary artery disease Jussi A. Hernesniemi, MD, PhD, Ville Vänni,

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Elliott P, et al. JAMA 2009;302:37-48.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Impact of prior hospital mortality versus surgical volume on mortality following surgery for congenital heart disease Matthew E. Oster, MD, Matthew J.

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Baseline Characteristics of the Subjects*

Dennis G. Moledina, MD, Mark A. Perazella, MD

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera, MD, MPhil, Dylan L. Steen, MD, MS, Irfan Khan, PhD, Robert P. Giugliano, MD, SM, JoAnne M. Foody, MD, FACC, FAHA Journal of Clinical Lipidology Volume 10, Issue 3, Pages 472-489 (May 2016) DOI: 10.1016/j.jacl.2015.11.010 Copyright © 2015 National Lipid Association Terms and Conditions

Figure 1 Association between absolute change in LDL-C levels over lifetime due to genetic variation and the change in relative risk for CHD. Based on data from Willer et al., 2008,27 Myocardial Infarction Genetics Consortium et al., 2014,29 Linsel-Nitschke et al., 2008,30 Cohen et al., 2006,33 Ference et al., 2012,34 and Stender et al., 201431 The figure has been limited to data from these studies regarding mutations with significant associations with both LDL-C levels and coronary outcomes. The studies were reviewed for duplicate reporting of data. Labels in the graph represent genes; repeated observations (e.g. LDLR) represent different SNPs. Where OR or HR were reported, change in relative risk was approximated as OR – 1 or HR – 1. The solid line represents estimated relationship via linear unweighted regression (Y = 0.0259 × X + 0.0173). CHD, coronary heart disease; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; SNP, single-nucleotide polymorphism. Journal of Clinical Lipidology 2016 10, 472-489DOI: (10.1016/j.jacl.2015.11.010) Copyright © 2015 National Lipid Association Terms and Conditions